certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Marsupial mulgaras have many resemblances to placental mice. Planigale has many resemblances to the deer mouse. The marsupial Tasmanian devil has many resemblances to the placental hyena or a wolverine. Similar skull morphology, large canines and crushing carnassial molars. Marsupial kangaroos and wallabies have many resemblances to the springhares, the viscachas (rodents which are also related to chinchillas), the maras (a large rodent from the cavy family (Caviidae)), and rabbits and hares (lagomorphs). The marsupial lion, Thylacoleo carnifex, had retractable claws, the same way the placental felines (cats) do today. Microbats, toothed whales and shrews developed sonar-like echolocation systems used for orientation, obstacle avoidance and for locating prey. Modern DNA phylogenies of bats have shown that the traditional suborder of echolocating bats (Microchiroptera) is not a true clade, and instead some echolocating bats are more related to non-echolocating Old World fruit bats than to other echolocating species. The implication is that echolocation in at least two lineages of bats, Megachiroptera and Microchiroptera has evolved independently or been lost in Old World fruit bats. Echolocation in bats and whales also both necessitate high frequency hearing. The protein prestin, which confers high hearing sensitivity in mammals, shows molecular convergence between the two main clades of echolocating bats, and also between bats and dolphins. Other hearing genes also show convergence between echolocating taxa.
=== Mo–Mu === Karl Friedrich Mohr (1806–1879), German chemist famous for early statement on the Conservation of energy Henri Moissan (1852–1907), French chemist and the winner of the 1906 Nobel Prize in Chemistry for his work on fluorine Mario J. Molina (1943–2020), Mexican chemist known for discovery of the Antarctic ozone hole, 1995 Nobel Prize in Chemistry Jacques Monod (1910–1976), French biochemist, winner of Nobel Prize in Physiology or Medicine in 1965 "for discoveries concerning genetic control of enzyme and virus synthesis" Jeffrey S. Moore (born 1961), American materials chemist known for work on macromolecular architectures Peter Moore (born 1939), American biochemist known for work on the structure, function, and mechanism of the ribosome Stanford Moore (1913–1982), American biochemist known for automatic amino acid analysis, 1972 Nobel Prize in Chemistry for work on the structure of the enzyme ribonuclease Henry Gwyn Jeffreys Moseley (1887–1915), British physicist who discovered Moseley's law and introduced the concept of atomic number Gerardus Johannes Mulder (1802–1880), Dutch organic chemist who introduced the concept of protein Paul Müller (1899–1965), Swiss chemist who discovered DDT and its use as an insecticide; Nobel Prize in Physiology or Medicine in 1939 Robert S.
The consequence of a broken ligament can be instability of the joint. Not all broken ligaments need surgery, but, if surgery is needed to stabilise the joint, the broken ligament can be repaired. Scar tissue may prevent this. If it is not possible to fix the broken ligament, other procedures such as the Brunelli procedure can correct the instability. Instability of a joint can over time lead to wear of the cartilage and eventually to osteoarthritis.
Sources: en.wikipedia.org
The word spectrograph had become part of the international scientific vocabulary by 1884. Early spectrometry devices that measured the mass-to-charge ratio of ions were called mass spectrographs which consisted of instruments that recorded a spectrum of mass values on a photographic plate. A mass spectroscope is similar to a mass spectrograph except that the beam of ions is directed onto a phosphor screen. A mass spectroscope configuration was used in early instruments when it was desired that the effects of adjustments be quickly observed. Once the instrument was properly adjusted, a photographic plate was inserted and exposed. The term mass spectroscope continued to be used even though the direct illumination of a phosphor screen was replaced by indirect measurements with an oscilloscope. The use of the term mass spectroscopy is now discouraged due to the possibility of confusion with light spectroscopy. Mass spectrometry is often abbreviated as mass-spec or simply as MS. Modern techniques of mass spectrometry were devised by Arthur Jeffrey Dempster and F.W. Aston in 1918 and 1919 respectively. Sector mass spectrometers known as calutrons were developed by Ernest O. Lawrence and used for separating the isotopes of uranium during the Manhattan Project. Calutron mass spectrometers were used for uranium enrichment at the Oak Ridge, Tennessee Y-12 plant established during World War II. In 1989, half of the Nobel Prize in Physics was awarded to Hans Dehmelt and Wolfgang Paul for the development of the ion trap technique in the 1950s and 1960s.
With insect infestation common in improperly stored provisions, soldiers would break up the hardtack and drop it into their morning coffee. This would not only soften the hardtack but the insects, mostly weevil larvae, would float to the top, and the soldiers could skim them off and eat the biscuits. The grubs "left no distinctive flavor behind." Some men turned hardtack into a mush by breaking it up with blows from their rifle butts, then adding water. If the men had a frying pan, they could cook the mush into a lumpy pancake; otherwise they dropped the mush directly on the coals of their campfire. They also mixed hardtack with brown sugar, hot water, and sometimes whiskey to create what they called a pudding, to serve as dessert.
== 1980 incident == On the evening of December 21, 1980, while celebrating Christmas with her family at their mansion, Clarendon Court, in Newport, Rhode Island, she again displayed confusion and lack of coordination. She was put to bed by her family, but in the morning she was discovered unconscious on the bathroom floor. She was taken to the hospital where it became clear that this time she had suffered severe enough brain injury to produce a persistent vegetative state. Although clinical features resembled a drug overdose, some of the laboratory evidence suggested hypoglycemia. The Court of Appeal ordered disclosure of the notes taken by the Auersperg children's attorney. These showed that Claus von Bülow did not want to terminate life support, as had been alleged. Because of the increased marital tensions between Claus and Sunny von Bülow in the fall of 1980, her children were suspicious that her brain injury was the result of foul play by him. Her two eldest children persuaded Richard H. Kuh, the former New York County District Attorney, to investigate the possibility Claus von Bülow had attempted the murder of their mother. After the gathering of evidence, Rhode Island prosecutors presented the case to a grand jury who returned an indictment, and in July 1981, he was charged with two counts of attempted murder.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.